Daniel Bowles
Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 31 | 2026 | 2192 | 3.380 |
Why?
| | Head and Neck Neoplasms | 16 | 2023 | 556 | 2.870 |
Why?
| | Salivary Gland Neoplasms | 8 | 2023 | 39 | 2.830 |
Why?
| | Protein Kinase Inhibitors | 15 | 2026 | 968 | 2.250 |
Why?
| | Carcinoma, Squamous Cell | 14 | 2019 | 641 | 2.220 |
Why?
| | Pyridines | 14 | 2026 | 605 | 2.130 |
Why?
| | Thyroid Neoplasms | 9 | 2024 | 343 | 1.840 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 9 | 2026 | 1180 | 1.710 |
Why?
| | Molecular Targeted Therapy | 7 | 2021 | 431 | 1.640 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 1137 | 1.550 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2021 | 433 | 1.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 1953 | 1.430 |
Why?
| | Neoplasms | 20 | 2024 | 2870 | 1.410 |
Why?
| | Lung Neoplasms | 11 | 2026 | 2637 | 1.390 |
Why?
| | Anilides | 6 | 2024 | 84 | 1.340 |
Why?
| | Gonanes | 7 | 2016 | 28 | 1.320 |
Why?
| | Proto-Oncogene Proteins | 6 | 2021 | 623 | 1.300 |
Why?
| | Thyroid Carcinoma, Anaplastic | 3 | 2020 | 36 | 1.250 |
Why?
| | Cetuximab | 7 | 2018 | 111 | 1.240 |
Why?
| | Biomarkers, Tumor | 8 | 2020 | 1313 | 1.210 |
Why?
| | Adenocarcinoma | 7 | 2024 | 927 | 1.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 8 | 2017 | 379 | 0.810 |
Why?
| | Pyrazoles | 6 | 2026 | 509 | 0.790 |
Why?
| | Mutation | 13 | 2024 | 4085 | 0.740 |
Why?
| | Pyrimidines | 6 | 2026 | 532 | 0.710 |
Why?
| | Carcinoma | 3 | 2019 | 227 | 0.710 |
Why?
| | Phytotherapy | 2 | 2012 | 74 | 0.690 |
Why?
| | Drugs, Investigational | 2 | 2011 | 31 | 0.680 |
Why?
| | Neoplasm Staging | 15 | 2019 | 1461 | 0.670 |
Why?
| | Cisplatin | 6 | 2024 | 334 | 0.670 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 100 | 0.620 |
Why?
| | Papillomaviridae | 4 | 2019 | 115 | 0.610 |
Why?
| | Disease-Free Survival | 10 | 2017 | 768 | 0.610 |
Why?
| | Taxoids | 3 | 2015 | 116 | 0.600 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 199 | 0.600 |
Why?
| | Quinolines | 5 | 2024 | 190 | 0.590 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 197 | 0.590 |
Why?
| | Carcinoma, Renal Cell | 3 | 2017 | 234 | 0.580 |
Why?
| | Humans | 90 | 2026 | 144261 | 0.580 |
Why?
| | Marijuana Smoking | 2 | 2012 | 250 | 0.550 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 321 | 0.550 |
Why?
| | Proto-Oncogene Proteins c-ret | 5 | 2026 | 40 | 0.550 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2024 | 881 | 0.540 |
Why?
| | Middle Aged | 44 | 2026 | 35762 | 0.520 |
Why?
| | Kidney Neoplasms | 3 | 2017 | 412 | 0.510 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 17 | 0.510 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 844 | 0.510 |
Why?
| | Aged | 40 | 2026 | 25850 | 0.500 |
Why?
| | Carcinoma, Transitional Cell | 4 | 2017 | 68 | 0.500 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2017 | 68 | 0.500 |
Why?
| | Carcinoma, Ductal | 1 | 2016 | 10 | 0.490 |
Why?
| | Adenoma, Pleomorphic | 1 | 2016 | 9 | 0.490 |
Why?
| | Sulfones | 2 | 2014 | 127 | 0.480 |
Why?
| | Gene Rearrangement | 2 | 2018 | 155 | 0.480 |
Why?
| | Cannabinoids | 2 | 2024 | 182 | 0.470 |
Why?
| | Glycine | 2 | 2014 | 187 | 0.470 |
Why?
| | Maximum Tolerated Dose | 5 | 2017 | 212 | 0.440 |
Why?
| | Melanoma | 1 | 2021 | 760 | 0.420 |
Why?
| | Drug Interactions | 6 | 2017 | 397 | 0.410 |
Why?
| | Enzyme Inhibitors | 3 | 2014 | 824 | 0.410 |
Why?
| | Pyrroles | 1 | 2014 | 217 | 0.400 |
Why?
| | Iodine Radioisotopes | 5 | 2024 | 136 | 0.390 |
Why?
| | Gene Fusion | 3 | 2023 | 29 | 0.390 |
Why?
| | Signal Transduction | 8 | 2018 | 5221 | 0.390 |
Why?
| | Phenylurea Compounds | 4 | 2024 | 112 | 0.390 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2012 | 230 | 0.380 |
Why?
| | Male | 45 | 2026 | 72035 | 0.380 |
Why?
| | Genetic Variation | 1 | 2018 | 982 | 0.380 |
Why?
| | Lymph Nodes | 4 | 2017 | 502 | 0.370 |
Why?
| | Aged, 80 and over | 16 | 2026 | 8243 | 0.370 |
Why?
| | Indazoles | 3 | 2019 | 80 | 0.370 |
Why?
| | Female | 46 | 2026 | 77976 | 0.360 |
Why?
| | Quinazolines | 1 | 2013 | 266 | 0.350 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2017 | 108 | 0.350 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 127 | 0.340 |
Why?
| | Treatment Outcome | 15 | 2024 | 11643 | 0.340 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 985 | 0.330 |
Why?
| | Neoplasm Metastasis | 6 | 2021 | 688 | 0.320 |
Why?
| | Adult | 27 | 2026 | 40262 | 0.310 |
Why?
| | Prognosis | 9 | 2021 | 4278 | 0.280 |
Why?
| | ErbB Receptors | 4 | 2017 | 627 | 0.280 |
Why?
| | Benzamides | 3 | 2022 | 224 | 0.270 |
Why?
| | Pharmacogenomic Variants | 2 | 2018 | 33 | 0.270 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 345 | 0.260 |
Why?
| | Urologic Neoplasms | 2 | 2017 | 31 | 0.250 |
Why?
| | Nitriles | 2 | 2022 | 205 | 0.250 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2007 | 88 | 0.250 |
Why?
| | Mitoxantrone | 1 | 2006 | 15 | 0.250 |
Why?
| | Platinum | 2 | 2024 | 50 | 0.250 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2024 | 928 | 0.240 |
Why?
| | Enterobacter | 1 | 2006 | 8 | 0.240 |
Why?
| | Tooth Diseases | 1 | 2006 | 13 | 0.240 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 36 | 0.240 |
Why?
| | Enterobacteriaceae Infections | 1 | 2006 | 41 | 0.230 |
Why?
| | Gene Expression Profiling | 5 | 2018 | 1782 | 0.230 |
Why?
| | Salivary Glands | 2 | 2023 | 36 | 0.230 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 55 | 0.230 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 862 | 0.230 |
Why?
| | Animals | 16 | 2024 | 38030 | 0.220 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.220 |
Why?
| | Chemoradiotherapy | 4 | 2020 | 237 | 0.220 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1050 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2024 | 225 | 0.220 |
Why?
| | Cannabis | 1 | 2011 | 509 | 0.210 |
Why?
| | Antiemetics | 1 | 2024 | 49 | 0.210 |
Why?
| | Receptors, Estrogen | 1 | 2007 | 457 | 0.210 |
Why?
| | Immunotherapy | 2 | 2023 | 652 | 0.210 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2026 | 210 | 0.210 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2017 | 255 | 0.210 |
Why?
| | Registries | 2 | 2016 | 2382 | 0.200 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 288 | 0.200 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2023 | 19 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1264 | 0.200 |
Why?
| | Bacteremia | 1 | 2006 | 221 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2019 | 1455 | 0.200 |
Why?
| | Models, Biological | 3 | 2024 | 1820 | 0.200 |
Why?
| | Administration, Oral | 3 | 2014 | 847 | 0.190 |
Why?
| | Phenylthiohydantoin | 1 | 2022 | 44 | 0.180 |
Why?
| | Medical Marijuana | 1 | 2024 | 123 | 0.180 |
Why?
| | Survival Rate | 5 | 2021 | 2088 | 0.180 |
Why?
| | Radiation Pneumonitis | 1 | 2021 | 31 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 194 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2017 | 419 | 0.170 |
Why?
| | Survival Analysis | 4 | 2020 | 1382 | 0.170 |
Why?
| | Referral and Consultation | 1 | 2007 | 847 | 0.170 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 35 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2020 | 346 | 0.160 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2021 | 65 | 0.160 |
Why?
| | Adrenocortical Carcinoma | 1 | 2021 | 67 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 449 | 0.160 |
Why?
| | Gene Expression | 2 | 2015 | 1487 | 0.160 |
Why?
| | Cystectomy | 2 | 2017 | 41 | 0.160 |
Why?
| | SEER Program | 1 | 2021 | 224 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 964 | 0.150 |
Why?
| | DNA Mutational Analysis | 2 | 2018 | 405 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2006 | 682 | 0.150 |
Why?
| | Lymph Node Excision | 2 | 2017 | 173 | 0.150 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 974 | 0.150 |
Why?
| | United States | 8 | 2021 | 15876 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2019 | 34 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 117 | 0.140 |
Why?
| | Alphapapillomavirus | 2 | 2016 | 35 | 0.140 |
Why?
| | Benzazepines | 1 | 2018 | 35 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 62 | 0.140 |
Why?
| | Risk | 1 | 2021 | 909 | 0.140 |
Why?
| | Disease Management | 2 | 2020 | 643 | 0.140 |
Why?
| | Genomics | 3 | 2021 | 833 | 0.140 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 162 | 0.140 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 52 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2017 | 36 | 0.130 |
Why?
| | Paraffin Embedding | 1 | 2017 | 32 | 0.130 |
Why?
| | Smokers | 1 | 2018 | 137 | 0.130 |
Why?
| | Oncogenes | 1 | 2018 | 119 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.130 |
Why?
| | Formaldehyde | 1 | 2017 | 66 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 20 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 387 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 141 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 163 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2018 | 307 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 279 | 0.130 |
Why?
| | Gene Frequency | 1 | 2018 | 481 | 0.120 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 87 | 0.120 |
Why?
| | Salivary Ducts | 1 | 2016 | 2 | 0.120 |
Why?
| | Palliative Care | 2 | 2018 | 996 | 0.120 |
Why?
| | Laryngeal Neoplasms | 1 | 2016 | 35 | 0.120 |
Why?
| | Muscle, Smooth | 1 | 2017 | 151 | 0.120 |
Why?
| | Carboplatin | 1 | 2016 | 160 | 0.120 |
Why?
| | Nomograms | 1 | 2016 | 59 | 0.120 |
Why?
| | Patient Navigation | 1 | 2018 | 104 | 0.120 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2018 | 107 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2026 | 0.120 |
Why?
| | Database Management Systems | 1 | 2016 | 50 | 0.120 |
Why?
| | Prospective Studies | 7 | 2024 | 7970 | 0.120 |
Why?
| | Disease Progression | 4 | 2018 | 2840 | 0.120 |
Why?
| | Population Surveillance | 1 | 2019 | 483 | 0.110 |
Why?
| | Young Adult | 5 | 2021 | 13990 | 0.110 |
Why?
| | Computational Biology | 2 | 2018 | 680 | 0.110 |
Why?
| | Angiopoietin-1 | 1 | 2015 | 12 | 0.110 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 15 | 0.110 |
Why?
| | Incidence | 2 | 2019 | 2870 | 0.110 |
Why?
| | Radiotherapy | 1 | 2016 | 206 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 253 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 478 | 0.110 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 17009 | 0.110 |
Why?
| | Retreatment | 1 | 2014 | 77 | 0.110 |
Why?
| | Hospice Care | 1 | 2018 | 217 | 0.110 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 21 | 0.110 |
Why?
| | Breast Neoplasms | 1 | 2007 | 2447 | 0.110 |
Why?
| | Piperazines | 2 | 2018 | 380 | 0.110 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 20 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 436 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 412 | 0.100 |
Why?
| | Paclitaxel | 1 | 2015 | 255 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 549 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2018 | 704 | 0.100 |
Why?
| | Veratrum Alkaloids | 1 | 2013 | 20 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 580 | 0.100 |
Why?
| | ras Proteins | 1 | 2014 | 150 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1255 | 0.100 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 1322 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 253 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2014 | 164 | 0.100 |
Why?
| | Cell Cycle Proteins | 2 | 2014 | 628 | 0.100 |
Why?
| | Pilot Projects | 2 | 2015 | 1867 | 0.090 |
Why?
| | Imatinib Mesylate | 1 | 2012 | 77 | 0.090 |
Why?
| | Dasatinib | 1 | 2012 | 57 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 674 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3637 | 0.090 |
Why?
| | Thiazoles | 1 | 2012 | 135 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1468 | 0.090 |
Why?
| | Aniline Compounds | 1 | 2012 | 119 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2015 | 420 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4254 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 75 | 0.090 |
Why?
| | Biological Availability | 1 | 2011 | 142 | 0.090 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 729 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2011 | 25 | 0.080 |
Why?
| | Imidazoles | 1 | 2012 | 254 | 0.080 |
Why?
| | Mice | 7 | 2024 | 18329 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2024 | 557 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22281 | 0.080 |
Why?
| | Propensity Score | 3 | 2017 | 367 | 0.080 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 732 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3539 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3157 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1834 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2359 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1495 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1533 | 0.070 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 109 | 0.070 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 706 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1318 | 0.070 |
Why?
| | Axilla | 1 | 2007 | 51 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 52 | 0.060 |
Why?
| | Cohort Studies | 4 | 2022 | 5935 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 462 | 0.060 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2007 | 118 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2014 | 2829 | 0.060 |
Why?
| | Transcription Factors | 1 | 2014 | 1739 | 0.060 |
Why?
| | Mastectomy | 1 | 2007 | 162 | 0.060 |
Why?
| | Ligation | 1 | 2006 | 92 | 0.060 |
Why?
| | Pain | 1 | 2011 | 777 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1147 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 505 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2006 | 307 | 0.060 |
Why?
| | Caregivers | 1 | 2014 | 1047 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 333 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 508 | 0.060 |
Why?
| | Receptors, Progesterone | 1 | 2007 | 356 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 11 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 19 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 2025 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 136 | 0.050 |
Why?
| | Isoquinolines | 1 | 2024 | 44 | 0.050 |
Why?
| | Skin Neoplasms | 1 | 2012 | 847 | 0.050 |
Why?
| | Risk Factors | 1 | 2019 | 10699 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 442 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 758 | 0.050 |
Why?
| | Demography | 2 | 2015 | 284 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2023 | 85 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2024 | 190 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 1134 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1484 | 0.040 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2021 | 38 | 0.040 |
Why?
| | Androgen Antagonists | 1 | 2022 | 91 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1715 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2021 | 83 | 0.040 |
Why?
| | Receptors, Androgen | 1 | 2022 | 153 | 0.040 |
Why?
| | Quality of Life | 1 | 2013 | 3166 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 149 | 0.040 |
Why?
| | Receptor, trkA | 1 | 2019 | 15 | 0.040 |
Why?
| | Receptor, trkC | 1 | 2019 | 10 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 77 | 0.040 |
Why?
| | Receptor, trkB | 1 | 2019 | 36 | 0.040 |
Why?
| | Trastuzumab | 1 | 2019 | 118 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 173 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 39 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 322 | 0.030 |
Why?
| | Phthalazines | 1 | 2018 | 64 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 10 | 0.030 |
Why?
| | Retroperitoneal Space | 1 | 2017 | 18 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 25 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2017 | 13 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 919 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 496 | 0.030 |
Why?
| | Social Work | 1 | 2018 | 85 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 51 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 322 | 0.030 |
Why?
| | Laryngectomy | 1 | 2016 | 16 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2018 | 259 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
| | Oncologists | 1 | 2017 | 46 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 118 | 0.030 |
Why?
| | Viral Core Proteins | 1 | 2016 | 22 | 0.030 |
Why?
| | Pelvis | 1 | 2017 | 124 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 229 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 998 | 0.030 |
Why?
| | Heart | 1 | 2020 | 633 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 222 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4556 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 156 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 363 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 1906 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 34 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1519 | 0.030 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2014 | 15 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 939 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2017 | 182 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1304 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 304 | 0.020 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 21 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 114 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 537 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1682 | 0.020 |
Why?
| | Gene Silencing | 1 | 2013 | 205 | 0.020 |
Why?
| | Nausea | 1 | 2012 | 111 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2104 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1044 | 0.020 |
Why?
| | Needs Assessment | 1 | 2014 | 401 | 0.020 |
Why?
| | Vomiting | 1 | 2012 | 130 | 0.020 |
Why?
| | Area Under Curve | 1 | 2012 | 329 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 682 | 0.020 |
Why?
| | Diarrhea | 1 | 2012 | 192 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 778 | 0.020 |
Why?
| | Fatigue | 1 | 2012 | 361 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2494 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 7155 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3313 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4108 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4562 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2061 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5389 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6021 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5813 | 0.010 |
Why?
|
|
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|